Question 1

What are the specific benefits of participating in this trial for my type of breast cancer?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03) clinical trial (NCT06874933). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to standard options available to me?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03) clinical trial (NCT06874933). Contact the study team or your healthcare provider for specific answers.

Question 3

What side effects should I expect from this combination of treatments?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03) clinical trial (NCT06874933). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for treatment and monitoring?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03) clinical trial (NCT06874933). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03) clinical trial (NCT06874933). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any long-term commitments or follow-ups required after the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03) clinical trial (NCT06874933). Contact the study team or your healthcare provider for specific answers.

What this study is about